Study identifier:D2782C00010
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase II, Single Arm, Single Agent, Multicentre, Adaptive 2-Stage Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD4877 Administered Weekly in Patients with Recurrent Advanced Urothelial Cancer
Bladder Cancer
Phase 2
No
AZD4877
All
54
Interventional
18 Years +
Allocation: N/A
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Dec 2010 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this Phase II study is to determine if AZD4877, an experimental drug that is a novel anti-mitotic agent (Eg5 or Kinesin Spindle Protein inhibitor that interferes with tumor cell division leading to tumor growth), can reduce tumor sizes in patients with bladder cancer
Location
Location
VANCOUVER, BC, Canada
Location
HALIFAX, NS, Canada
Location
TORONTO, ON, Canada
Location
MONTREAL, QC, Canada
Location
QUEBEC, QC, Canada
Location
BERLIN, Germany
Location
DRESDEN, Germany
Location
DUSSELDORF, Germany
Arms | Assigned Interventions |
---|---|
Experimental: AZD4877 Single agent AZD4877 | Drug: AZD4877 Intravenous (IV)25mg/weekly |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.